U.S. Department of Defense Awards Kerecis a Grant to Develop and Test New Fish-skin Wound Treatment for Soldiers
“We understand that it is becoming more and more difficult to evacuate wounded soldiers from combat zones because of factors such as remote battle environments and advanced ground-combat weapons,” said Fertram Sigurjonsson, founder and CEO of Kerecis. “The medics in the field need the most advanced medical resources to provide the best field care possible for wounded soldiers. Our goal is to develop a combat-zone, fish-skin technology that can provide superior wound care for injured American service people.”
Specifically, Kerecis will develop and test a field-specific application of its fish-skin technology to advance the treatment of complicated soft-tissue injuries while injured soldiers are being evacuated from Echelon 2 and 3 field hospitals to Echelon 4+ health care facilities.
About the Grant
The award is the company’s third grant from the DoD. The work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Defense Medical Research and Development Program under Award No. W81XWH2020058. The grant is part of the Combat Casualty Care Research Program (JPC-6), Multi-Domain Lifesaving Trauma Innovations (MuLTI) Award. The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014, is the awarding and administering acquisition office. The grant money will be disbursed to Kerecis over three years.
About Kerecis Omega3
Kerecis Omega3 is intact fish skin that is used to regenerate and protect human tissue. Because no disease-transfer risk exists between cold-water fish and humans, the Kerecis fish skin is only gently processed and retains its similarity to human skin, making it ideal for treating wounded soldiers. The intact fish skin contains Omega3 fatty acids and all the natural building components of skin, offering benefits such as bacterial barrier to protect the wound bed.
In conducting research using animals, the investigator(s) adheres to the laws of the United States and regulations of the Department of Agriculture.
Kerecis is pioneering the use of fish skin and fatty acids in the globally expanding cellular- therapy and regenerative-medicine market. The company’s fatty-acid-rich intact fish skin protects the body’s tissues and enables the body to regenerate tissues. The Kerecis sprayable fatty-acid topical and oral formulations protect the body from bacterial and viral infections. The company’s products are currently being used to regenerate tissue in diabetic and trauma wounds (including burns) and for infection control. Kerecis is also developing products for areas such as oral surgery, plastic surgery and neurological applications. The company’s mission is to extend human life by supporting the body’s own ability to regenerate, and its vision is to become the world leader in tissue regeneration by sustainably harnessing nature’s own remedies. For more information, visit www.kerecis.com
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.